Citi Pharma Limited Stock

Equities

CPHL

PK0126201018

Pharmaceuticals

End-of-day quote Pakistan S.E. 18:00:00 2024-05-15 EDT 5-day change 1st Jan Change
31.62 PKR +1.48% Intraday chart for Citi Pharma Limited -4.07% +33.19%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 9.78B 35.17M 47.87M Sales 2023 12.4B 44.58M 60.68M Capitalization 4.88B 17.53M 23.86M
Net income 2022 636M 2.29M 3.11M Net income 2023 658M 2.37M 3.22M EV / Sales 2022 0.65 x
Net cash position 2022 1.05B 3.79M 5.16M Net Debt 2023 262M 943K 1.28M EV / Sales 2023 0.41 x
P/E ratio 2022
11.7 x
P/E ratio 2023
7.41 x
Employees 594
Yield 2022 *
-
Yield 2023
11.7%
Free-Float 45.19%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.48%
1 week-4.07%
Current month+19.86%
1 month+30.66%
3 months+48.80%
6 months+21.57%
Current year+33.19%
More quotes
1 week
30.90
Extreme 30.9
33.18
1 month
24.11
Extreme 24.11
33.85
Current year
20.01
Extreme 20.01
33.85
1 year
19.07
Extreme 19.07
33.85
3 years
19.07
Extreme 19.07
50.05
5 years
19.07
Extreme 19.07
50.05
10 years
19.07
Extreme 19.07
50.05
More quotes
Managers TitleAgeSince
Chief Executive Officer - 12-10-07
Director of Finance/CFO - 19-10-31
Director/Board Member - 20-10-12
Members of the board TitleAgeSince
Director/Board Member - -
Chairman - 12-10-07
Chief Executive Officer - 12-10-07
More insiders
Date Price Change Volume
24-05-16 31.62 +1.48% 2,905,334
24-05-15 31.16 -1.24% 3,540,011
24-05-14 31.55 -1.00% 3,438,095
24-05-13 31.87 -2.03% 2,192,423
24-05-10 32.53 -1.30% 5,815,614

End-of-day quote Pakistan S.E., May 15, 2024

More quotes
Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
31.62
Average target price
-
Consensus

Annual profits - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW